This is a StreetInsider.com Premium Only Page

Stemline Therapeutics (STML) – Globe Newswire

May 21, 2020 02:10 PM SHAREHOLDER ALERT: WeissLaw LLP Reminds STML, PTLA, and QES Shareholders About Its Ongoing Investigations

May 19, 2020 12:23 PM STEMLINE ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of STML and Encourages Investors to Contact the Firm

May 14, 2020 05:30 PM SHAREHOLDER ALERT: WeissLaw LLP Reminds STML, PTLA, QES, and TERP Shareholders About Its Ongoing Investigations

May 4, 2020 07:00 AM Menarini Group to Acquire Stemline Therapeutics in Transaction Valued at Up to $677 Million

Mar 13, 2020 04:45 PM Stemline Therapeutics Reports Fourth Quarter 2019 Financial Results

Mar 11, 2020 04:05 PM Stemline Therapeutics to Host Conference Call on Fourth Quarter 2019 Financial Results on March 16, 2020

Feb 26, 2020 07:30 AM Stemline Therapeutics to Present at the Cowen 40th Annual Health Care Conference

Jan 13, 2020 04:15 PM Stemline Therapeutics Announces Preliminary 2019 Net Revenues for ELZONRIS® (tagraxofusp) and Highlights Commercial and Clinical Growth Drivers

Jan 8, 2020 04:15 PM Stemline Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

Dec 10, 2019 08:00 AM Stemline Therapeutics Recaps ELZONRIS Clinical Data Presentations in Patients with Myelofibrosis (oral presentation) and Multiple Myeloma at the 61st American Society of Hematology (ASH) Annual Meetin

Dec 6, 2019 06:30 PM Stemline Therapeutics Names Robert M. Francomano Chief Commercial Officer

Dec 6, 2019 07:00 AM Stemline Therapeutics Highlights Three ELZONRIS Presentations, Including an Oral Presentation in Myelofibrosis, at Upcoming ASH Meeting

Nov 29, 2019 01:05 PM Stemline Therapeutics to Present at Piper Jaffray’s 31st Annual Healthcare Conference

Nov 7, 2019 04:57 PM Stemline Therapeutics Reports Third Quarter 2019 Financial Results

Nov 6, 2019 09:15 AM Stemline Therapeutics Announces Three ELZONRIS Presentations, Including an Oral Presentation in Myelofibrosis, at Upcoming ASH Meeting

Nov 5, 2019 04:22 PM Stemline Therapeutics to Host Conference Call on Third Quarter 2019 Financial Results on November 8, 2019

Oct 8, 2019 07:30 AM Stemline Therapeutics Announces ELZONRIS® Clinical Data Selected for Oral Presentation at the 81st Annual Meeting of the Japanese Society of Hematology

Oct 1, 2019 07:30 AM Stemline Therapeutics Recaps Felezonexor (SL-801) Clinical Data Presentation From ESMO 2019 Congress

Sep 27, 2019 07:30 AM Stemline Therapeutics Announces Felezonexor (SL-801) Clinical Data to be Featured at Upcoming ESMO 2019 Congress

Sep 26, 2019 04:01 PM Stemline Therapeutics to Present at the 2019 Cantor Global Healthcare Conference

Sep 18, 2019 09:32 AM Stemline Therapeutics to Present at the Ladenburg Thalmann 2019 Healthcare Conference

Sep 5, 2019 07:30 AM Stemline Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference

Aug 9, 2019 04:00 PM Stemline Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference

Aug 8, 2019 10:23 PM Stemline Therapeutics Announces Pricing of $76,250,000 Public Offering of Common Stock

Aug 7, 2019 04:25 PM Stemline Therapeutics Announces Proposed Public Offering of Common Stock

Aug 6, 2019 07:30 AM Stemline Therapeutics Announces that CMS Grants New Technology Add-on Payment (NTAP) to ELZONRIS®

Aug 2, 2019 07:00 AM Stemline Therapeutics Reports Second Quarter 2019 Financial Results

Jul 29, 2019 07:00 AM Stemline Therapeutics to Host Conference Call on Second Quarter 2019 Financial Results on August 2, 2019